[Correspondence] Is it time to convert the frequency of radiotherapy in small-cell lung cancer?

We congratulate Corinne Faivre-Finn and colleagues on their critical phase 3 CONVERT study1 demonstrating non-significant differences in survival outcomes with once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer, with a median overall survival of 25 months in the once-daily group versus 30 months in the twice-daily group (HR 1·18, 95% CI 0·95–1·45; p=0·14), 2-year overall survival of 51% versus 56%, and 5-year overall survival of 31% versus 34%.

http://ift.tt/2xMhUPg